iMDx Appoints Dr. Nick Ioannou as Vice President of Medical Affairs
NASHVILLE, Tenn., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX), also known as iMDx, has announced the appointment of Dr. Nick Ioannou, M.D., MHA, to the role of Vice President of Medical Affairs. With over **30 years of experience** across academia, industry, and clinical settings, Dr. Ioannou is expected to play a pivotal role in advancing iMDx's goals, particularly as the company prepares for the launch of its commercial transplant assay.
Dr. Ioannou's Extensive Background in Medical Affairs
Dr. Ioannou brings a wealth of knowledge in various therapeutic areas, including organ transplantation, nephrology, cardiology, genetics, and oncology. His career includes over **15 years of field-based collaboration** with key opinion leaders, which positions him as a valuable asset for iMDx as it seeks to enhance its medical affairs strategy.
Before joining iMDx, Dr. Ioannou held several prominent roles, such as:
- Senior Staff Medical Science Liaison and Field Director at Guardant Health.
- Medical Science Liaison for organ health and genetics at Natera.
- Director of Medical Education and Medical Communications at LA Ort Institute.
- Director of Medical Affairs at L-Nutra.
- International Medical Science Liaison for heart and kidney transplant at CSL Behring.
His experience as a medical director and partner in private clinics over nearly a decade has equipped him with a strong ability to foster relationships with patients and healthcare professionals alike.
Leadership Insight from iMDx CEO
"Dr. Ioannou is a perfect fit for iMDx at this pivotal time given his medical advisory experience in organ transplant, nephrology, cardiology, oncology, and genetics," said Josh Riggs, CEO of iMDx. "His leadership and network will be essential as we launch our first commercial products." This statement reflects the company's confidence in Dr. Ioannou's ability to bridge communication between various stakeholders during this crucial period.
Dr. Ioannou expressed his enthusiasm for joining iMDx, stating, “I am thrilled to join a team innovating at a rapid pace and poised to become a leader in transplant rejection testing. The market is demanding a better transplant rejection testing paradigm, and I look forward to delivering diagnostics that enhance patient care.”
Academic Credentials and Expertise
Dr. Ioannou holds a Bachelor of Science in Microbiology from California State University, Northridge, and a Master of Healthcare Administration from Saint Joseph's College of Maine. He completed his Medical Doctorate clinical training at Michael Reese Hospital in Chicago, solidifying his foundation in both medical practice and healthcare management.
About Insight Molecular Diagnostics, Inc.
Insight Molecular Diagnostics is dedicated to democratizing access to innovative molecular diagnostic testing with the aim of improving patient outcomes. Investors can find more information on iMDx's initiatives and projects at investors.imdxinc.com.
Trademarks of Insight Molecular Diagnostics Inc. include GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™.
Forward-Looking Statements Disclaimer
This press release may contain forward-looking statements that involve risks and uncertainties. Such statements include, but are not limited to, those about Dr. Ioannou's appointment and expected contributions to iMDx. Investors are cautioned not to place undue reliance on these statements, as actual results may differ due to various factors, including regulatory approvals and market conditions.